MILIO, Glauco
 Distribuzione geografica
Continente #
NA - Nord America 2.432
EU - Europa 1.588
AS - Asia 389
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 4.414
Nazione #
US - Stati Uniti d'America 2.427
IT - Italia 471
UA - Ucraina 360
CN - Cina 317
FI - Finlandia 261
DE - Germania 116
IE - Irlanda 110
GB - Regno Unito 76
SE - Svezia 50
FR - Francia 43
RU - Federazione Russa 36
BE - Belgio 26
TR - Turchia 18
KR - Corea 17
IN - India 16
RO - Romania 14
IR - Iran 9
CH - Svizzera 8
AT - Austria 4
HK - Hong Kong 4
CA - Canada 3
GR - Grecia 3
LB - Libano 3
BO - Bolivia 2
ES - Italia 2
HR - Croazia 2
NL - Olanda 2
UZ - Uzbekistan 2
AL - Albania 1
BR - Brasile 1
CR - Costa Rica 1
EU - Europa 1
IL - Israele 1
JP - Giappone 1
MD - Moldavia 1
MX - Messico 1
NZ - Nuova Zelanda 1
PL - Polonia 1
PT - Portogallo 1
SG - Singapore 1
Totale 4.414
Città #
Chandler 279
Fairfield 222
Jacksonville 198
Ashburn 192
Ann Arbor 170
Woodbridge 163
Wilmington 141
Houston 113
Dublin 110
Medford 85
Seattle 77
Nanjing 74
Cambridge 71
Des Moines 70
Palermo 53
Princeton 53
Tulsa 50
Boardman 34
Dearborn 29
Brussels 25
Jinan 25
San Diego 24
Shenyang 24
Altamura 21
Hebei 21
Nanchang 20
San Mateo 20
Changsha 19
Jiaxing 19
New York 19
Beijing 17
Izmir 17
Milan 17
Lawrence 13
Seongnam 13
Tianjin 13
Rome 12
Ningbo 11
Zhengzhou 11
Pune 10
Verona 10
Ludwigshafen am Rhein 9
Auburn Hills 8
Catania 8
Taizhou 8
Bari 7
Lanzhou 7
Tehran 7
Falls Church 6
Guangzhou 6
Kunming 6
Munich 6
Bremen 5
Haikou 5
London 5
Mykolayiv 5
Redwood City 5
Reseda 5
Saint Petersburg 5
Torino 5
Enna 4
Hangzhou 4
Kumar 4
Los Angeles 4
Medolago 4
Mirano 4
Naples 4
Orange 4
Shanghai 4
Taiyuan 4
Venice 4
Central District 3
Fuzhou 3
Hefei 3
Monza 3
Norwalk 3
Redmond 3
Ancona 2
Bolzano 2
Catanzaro 2
Florence 2
Genoa 2
Genova 2
Hanover 2
Kiev 2
Kilburn 2
La Paz 2
Lleida 2
Mediglia 2
Monselice 2
Napoli 2
New Delhi 2
Novi 2
Ozieri 2
Padova 2
Piacenza 2
Porto Torres 2
San Colombano al Lambro 2
Torregrotta 2
Vicenza 2
Totale 2.791
Nome #
Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol 176
Pharmacological Treatment of Patients with Chronic Critical Limb Ischemia: L-Propionyl-Carnitine Enhances the Short-Term Effects of PGE-1 147
Ischemia critica cronica e vasculopatia ischemica polidistrettuale 145
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: The Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study 139
Asymptomatic Carotid Lesions and Aging: Role of Hypertension and Other Traditional and Emerging Risk Factors 133
Critical limb ischaemia: definition and natural hystory 130
Modello di percorso diagnostico e terapeutico per l'arteriopatia obliterante periferica 130
Antiplatelet treatment in ischemic stroke treatment. 123
Asymptomatic carotid lesions and aging: role of hypertension and other traditional and emerging risk factors 122
Changes of arterial hemodynamics in patients with type 2 diabetes mellitus or impaired glucose tolerance 118
Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins 115
Subclavean stenosis/occlusion in patients with subclavean steal and previous by pass of internal mammary interventricular anterior artery: medical or surgery treatment? 114
Response to letter by Drs. Mohammed Abbas, Maria Sessa, and Francesco Corea 103
null 100
Modello di percorso diagnostico e terapeutico per la trombosi venosa superficiale 98
Residual vein thrombosis assessment estabilishes the optimal duration of oral anticoagulants in patients with idiopatic or provoked deep vein thrombosis 95
Sodium thiosulfate not always resolves calciphylaxis: an ambiguous response 93
Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial 92
Stress ossidativo in pazienti con sclerodermia: effetti dell’iloprost. 90
Immunohistochemical expression of iNOS and metalloproteinases MMP2 and MMP9 in abdominal inflammatory aortic Aneurysms 88
La terapia metabolica nel trattamento dell'ischemia critica cronica degli arti inferiori: la L-propionilcarnetina potenzia gli effetti della PGE-1 85
Effetti dell’iloprost sulla disfunzione leucocitaria nella sclerodermia. 83
Effetti emoreologici del trattamento con iloprost in pazienti con fenomeno di Raynaud secondario a sclerodermia. 79
THE EFFECTS OF PROSTAGLANDIN E-1 IN PATIENTS WITH INTERMITTENT CLAUDICATION 79
Residual vein thrombosis assessment establishes the otpimal duration of oral anticoagulants in patients with idiopathic or provoked deep vein thrombosis 76
Moderno approccio alla trombosi venosa superficiale 75
Aspetti fisiopatologici dell'ulcera venosa 74
Absence of residual vein thrombosis after an episode of idiopatic deep vein thrombosis: short-term anticoagulation is safe. The extended DACUS study. 74
Absence of residual vein thrombosis after an episode of idiopatic deep vein thrombosis: short-term anticoagulation is safe. The extended DACUS Study 74
MTHFR allele 677T band risk of abdominal aortic aneurysm 73
Calf vein thrombosis: optimal duration of treatment 70
Residual vein thrombosis estabilishes the optimal duration of oral anticoagulants for the treatment od DVT 68
Residual Vein Thrombosis Assessment Establishes the Optimal Duration of Oral Anticoagulants in Patients with Idiopathic or Provoked Deep Vein Thrombosis: a Randomized, Controlled Trial 65
Superficial venous thrombosis: role of genetic risk factors on spreeding to deep veins 65
SUPERFICIAL VENOUS THROMBOSIS: ROLE OF GENETIC RISK FACTORS ON SPREADING TO DEEP VEINS 64
Calf vein thrombosis: optimal duration of tretment 64
Trombosi venosa superficiale ed estensione al circolo profondo: ruolo dei fattori di rischio genetici 63
Residual vein thrombosis assessment estabilishes the optimal duration of oral anticoagulants in patients with idiopatic or provoked deep vein thrombosis. a randomized, controlled trial 58
Calf veins thrombosis: optimal duration of treatment 58
Peso dei fattori di rischio nell’evoluzione dell’aterosclerosi preclinica 58
Metabolic therapy in the treatment of chronic critical limbs ischemia: the L-propionyl-carnitine enhances the effects of PGE-1 57
null 57
Immunohistochemical expression of iNOS and eNOS in the venous ulcers related to chronic venous insufficiency (CVI). 56
Ischemia critica e connettiviti: presupposti fisiopatologici per un protocollo di trattamento 56
The effects Prostaglandine E-1 in patients with intermittent claudication 55
Trattamento delle manifestazioni vascolari nella Sclerosi Sistemica e qualità della vita: nuovo protocollo 54
The effects of Prostaglandin E-1in patients with intermittent claudication 53
Comportamento della eNOS e dell'iNOS nella genesi e mantwnimento delle ulcere venose degli arti inferiori 52
TROMBOSI PROFONDA SUPERFICIALE ED ESTENSIONE AL CIRCOLO PROFONDO: RUOLO DEI FATTORI DI RISCHIO GENETICI 49
Superficial venous thrombosis and spreading to deep veins: role of genetic risk factors for venous thromboembolism 49
METABOLIC THERAPY IN THE TREATMENT OF CHRONIC CRITICAL LIMBS ISCHEMIA OF THE LOWER LIMBS. THE L-PROPIONYL-CARNITINE ENHANCES THE EFFECTS OF PGE-1 45
Rilievi emoreologici nella sclerosi sistemica. 45
Il trattamento domiciliare della TVP 37
Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs 30
NO and Chronic Venous Insufficiency (CVI): Immunohistochemical Evaluation of iNOS and eNOS Isofroms in the Venous Ulcers. Clinical and Therapeutical Possible Implications 20
Totale 4.471
Categoria #
all - tutte 12.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.997


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019185 0 0 0 0 0 0 0 0 0 29 82 74
2019/2020980 128 23 64 49 103 115 109 43 101 42 127 76
2020/2021629 16 76 48 64 71 32 59 31 77 20 71 64
2021/2022539 18 139 5 35 20 7 27 23 65 68 20 112
2022/2023762 82 97 9 87 86 117 64 63 94 16 41 6
2023/2024257 14 48 17 31 21 79 33 7 1 6 0 0
Totale 4.471